Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

33 results about "Mesodermal cell" patented technology

The mesoderm forms mesenchyme, mesothelium, non-epithelial blood cells and coelomocytes. Mesothelium lines coeloms. Mesoderm forms the muscles in a process known as myogenesis, septa (cross-wise partitions) and mesenteries (length-wise partitions); and forms part of the gonads (the rest being the gametes).

Multipotent stem cells derived from placenta tissue and cellular therapeutic agents comprising the same

InactiveUS20070243172A1Negative immunological responseBiocideArtificial cell constructsGerm layerDisease
The present invention relates to placenta tissue-derived multipotent stem cells and cell therapeutic agents containing the same. More specifically, to a method for producing placenta stem cells having the following characteristics, the method comprising culturing amnion, chorion, decidua or placenta tissue in a medium containing collagenase and bFGF and collecting the cultured cells: (a) showing a positive immunological response to CD29, CD44, CD73, CD90 and CD105, and showing a negative immunological response to CD31, CD34, CD45 and HLA-DR; (b) showing a positive immunological response to Oct4 and SSEA4; (c) growing attached to plastic, showing a round-shaped or spindle-shaped morphology, and forming spheres in an SFM medium so as to be able to be maintained in an undifferentiated state for a long period of time; and (d) having the ability to differentiate into mesoderm-, endoderm- and ectoderm-derived cells. Also the present invention relates to placenta stem cells obtained using the production method. The inventive multipotent stem cells have the ability to differentiate into muscle cells, vascular endothelial cells, osteogenic cells, nerve cells, satellite cells, fat cells, cartilage-forming cells, osteogenic cells, or insuline-secreting pancreatic β-cells, and thus are effective for the treatment of muscular diseases, osteoporosis, osteoarthritis, nervous diseases, diabetes and the like, and are useful for the formation of breast tissue.
Owner:RNL BIO

Method of inducing differentiation from pluripotent stem cells to skeletal muscle progenitor cells

Provided is a method of producing a skeletal muscle progenitor cell using a pluripotent stem cell, particularly an iPS cell, the method comprising the step 1) of culturing a pluripotent stem cell under serum-free conditions, and in the presence of Activin A, to allow the cell to differentiate into a PDGFRα-positive mesodermal cell, and the step 2) of culturing the mesodermal cell under serum-free conditions, and in the presence of a Wnt signal inducer, to allow the cell to differentiate into a skeletal muscle progenitor cell. Also provided are a cell population containing a skeletal muscle progenitor cell as obtained by the method, and a skeletal muscle regeneration promoting agent and therapeutic agent for muscular diseases such as muscular dystrophy, the promoting agent or agent comprising the skeletal muscle progenitor cell as an active ingredient.
Owner:KYOTO UNIV

Pharmaceutical composition for treating female reproductive track infection and preparation method thereof

The invention discloses a pharmaceutical composition for treating female reproductive track infection and a preparation method thereof. The pharmaceutical composition comprises polylysine microspheres, fructus ligustri lucidi, radix sophorae flavescentis, fructus cnidii, Chinese usnea, poloxamer F127 and poloxamer F68, wherein the content of the polylysine microspheres is 0.01-0.05% by mass percent; the total content of fructus ligustri lucidi, radix sophorae flavescentis, fructus cnidii and Chinese usnea is 1-7%; the ratio of fructus ligustri lucidi to radix sophorae flavescentis to fructus cnidii to Chinese usnea is 1:1:2:1; the content of poloxamer F12 is 17-30%; the content of F68 is 0-20%; and the rest is water. After the polylysine microspheres and the traditional Chinese medicine composition are compounded, vaginal wound healing is effectively promoted. The pharmaceutical composition has a repair and regeneration promotion function on cells of a mesoderm and an ectoderm, and canpromote regeneration of blood capillaries, improve the local blood circulation and quicken wound healing. Polylysine becomes amino acid after being decomposed and can serve as a nutrient substance tobe absorbed.
Owner:成都山信药业有限公司

Antagonists of BMP and TGF beta signalling pathway

This invention provides unique members of the Hect family of ubiquitin ligases that specifically target BMP and TGF beta / activin pathway-specific Smads. The novel ligases have been named Smurf1 and Smurf2. They directly interact with Smads1 and 5 and Smad7, respectively, and regulate the ubiquitination, turnover and activity of Smads and other proteins of these pathways. Smurf1 interferes with biological responses to BMP, but not activin signalling. In amphibian embryos Smurf1 inhibits endogenous BMP signals, resulting in altered pattern formation and cell fate specification in the mesoderm and ectoderm. The present invention provides a unique regulatory link between the ubiquitination pathway and the control of cell fate determination by the TGF beta superfamily during embryonic development. Thus, Smurf1 is a negative regulator of Smad1 signal transduction, by targeting Smad1, Smurf1 blocks BMP signalling. In mammalian cells, Smurf2 suppresses TGF beta signalling, and in Xenopus, blocks formation of dorsal mesoderm and causes anterior truncation of the embryos. Smurf2 forms a stable complex with Smad7, which induces degradation and downregulation of TGF beta / activin signalling.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK +1

Induced presomitic mesoderm (IPSM) cells and their use

The invention relates to a method for reprogramming target cells to multipotent progenitor cells capable of differentiating into muscular, skeletal or dermal cell lines. In particular, the invention relates to an ex vivo method for preparing induced presomitic mesoderm (iPSM) cells, said method comprising the steps of: a) providing target cells to be reprogrammed, and, b) culturing said target cells under appropriate conditions for reprogramming said target cells into iPSM cells, wherein said appropriate conditions comprises increasing expression of at least one T-Box transcription factor in said target cells. The invention further relates to the use of said iPSM cells, for example, for regenerating skeletal, muscle, dermal and cartilage tissues.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3

Method of generating neural stem cells

The present invention relates to a method of generating neural stem cells from mesodermal cells. The invention further provides a cell population which has neural stem cell-like characteristics. The neural stem cells prepared according to the invention are useful in the treatment of neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease.
Owner:NEUROPROGEN LEIPZIG

Method for determining undifferentiated state of pluripotent stem cell, method for subculturing pluripotent stem cell, and device for use in said methods

The present disclosure provides a method for determining the undifferentiated state of a pluripotent stem cell, the method comprising irradiating a culture medium being tested in which the pluripotentstem cell is cultured, with light having wavelengths in all or a part of the range of 190-2500 nm, detecting reflected light, transmitted light, or transmitted and reflected light thereof to obtain absorbance spectral data, and analyzing the absorbances in all or in a partial range of the measured wavelengths of the absorbance spectral data, on the basis of an analysis model which is previously created using a plurality of types of control culture media used in culturing the pluripotent stem cell, to determine the undifferentiated state of the pluripotent stem cell, wherein the plurality of types of control culture media include one or more differentiation-inducing media selected from a medium used in maintaining the undifferentiated state of the pluripotent stem cell, a medium for inducing differentiation to an ectodermal cell, a medium for inducing differentiation to a mesodermal cell, and a medium for inducing differentiation to an endodermal cell.
Owner:TOKYO ELECTRON LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products